HIF1A and neoplasm: Since HIF-1 inhibitors would be expected to downregulate expression of glycolytic enzymes and thus inhibit flux through the glycolytic pathway, the obvious way to test the action of such drugs on tumours would be to look for suppression of 18FDG uptake using PET.